TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32356286
Drug: CORDIS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORDIS group treatment program (10-week modularized treatment)
Study: 35358461
Drug: Screening spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening spinal MRI and pre‐emptive treatment for spinal cord compression
Study: 32306007
Drug: Oral pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pyrotinib (400 mg once daily or 320 mg)
Study: 33340343
Drug: Cefprozil for
Normalized name: Cefprozil for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil for suspension (125 mg) under fasted conditions
Study: 33340343
Drug: Cefprozil for
Normalized name: Cefprozil for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil for suspension (125 mg) under fed conditions
Study: 33340343
Drug: Granule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granule formulation of cefprozil
Study: 34979962
Drug: Stepped-dose furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stepped-dose furosemide (SF) - continuous infusion of furosemide 100 mg on day 1, with daily incremental doses to 200 mg, 300 mg, and 400 mg.
Study: 34979962
Drug: Combined diuretics
Normalized name: atenolol and other diuretics, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined diuretics (CD) - combination of oral chlorthalidone 50 mg, spironolactone 50 mg, and infusion of furosemide 100 mg for 4 consecutive days.
Study: 34738551
Drug: Nicorandil (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (24 mg/d intravenously for 1 week)
Study: 35851689
Drug: Metronidazole (MTZ)
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole (MTZ) + Amoxicillin (AMX)
Study: 32543706
Drug: rhBMP6/ABC (1.0 mg/10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBMP6/ABC (1.0 mg/10 mL ABC)
Study: 32543706
Drug: Placebo (10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mL ABC containing excipients)
Study: 33176593
Drug: 30 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes of NMES daily (Group B)
Study: 33176593
Drug: 60 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 minutes of NMES daily (Group C)
Study: 35580859
Drug: Liraglutide in
Normalized name: Liraglutide Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide in combination with exercise training
Study: 37204788
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (<120 mm Hg)
Study: 37204788
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (<140 mm Hg)
Study: 35006243
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment vs non-Hispanic Black
Study: 35006243
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment vs non-Hispanic Black
Study: 35006243
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment vs Hispanic
Study: 35006243
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment vs Hispanic
Study: 33828354
Drug: Criminal Justice
Normalized name: Justicia spicigera leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Criminal Justice (CJ) mandated treatment
Study: 33828354
Drug: Child Protective
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child Protective Services (CPS) mandated treatment
Study: 33828354
Drug: Nonmandated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmandated treatment
Study: 35149566
Drug: Elobixibat (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elobixibat (an ileal bile acid transporter inhibitor)
Study: 35987909
Drug: Glabellar botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glabellar botulinum toxin (BTX) injections
Study: 35074904
Drug: High-dose interferon-alfa
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon-alfa (HDI)
Study: 34120628
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (knee brace and outpatient physical therapy)
Study: 34120628
Drug: Tailored patella
Normalized name: Blatella germanica
DrugBank: Blatella germanica (DB10418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored patella stabilizing surgical treatment
Study: 34016663
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation with food rations (750 kcal and 23 g proteins/day) and multivitamins for HHC
Study: 34016663
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (monthly food rations supplying 1200 kcal and 52 g proteins/day) and multivitamins along with antitubercular treatment for patients
Study: 35994789
Drug: Nedaplatin 30
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedaplatin 30 mg/m2
Study: 33082512
Drug: Prednisolone (2–2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (2–2.5 mg/kg)
Study: 35897006
Drug: rt‐PA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA + T group (low-dose rt-PA 0.6 mg/kg + tirofiban for 24 hours)
Study: 35897006
Drug: rt‐PA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA group (standard dose rt-PA 0.9 mg/kg)
Study: 33482030
Drug: Ultraviolet radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultraviolet radiation (UV) treatment
Study: 33482030
Drug: Sulphuric acid-based
Normalized name: Sulfuric Acid
DrugBank: Sulfuric acid (DB11309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphuric acid-based fertilizer (SA) treatment
Study: 32959431
Drug: Virtual screen‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual screen‐based stress management programme (V‐DESSERTS), individual‐based, twice‐daily sessions
Study: 33140499
Drug: Group-based motor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based motor and cognitive combined intervention (8-week program, group exercise and cognitive stimulation, twice per week for 45 min)
Study: 33561623
Drug: Capsaicin (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (early administration)
Study: 38986791
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral treprostinil
Study: 34881930
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help cognitive-behavioral therapy (3 months)
Study: 34819115
Drug: Daily healthy
Normalized name: Walgreens One Daily Healthy Weight Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily healthy behavior text messaging and weekly self-measured blood pressure monitoring
Study: 32028393
Drug: Duloxetine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (2 × 40 mg daily) + Pelvic Floor Muscle Training (PFMT) for 12 weeks
Study: 32028393
Drug: Duloxetine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (2 × 40 mg daily)
Study: 35836478
Drug: Koji amazake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Koji amazake (118 g/day)
Study: 32319204
Drug: Low-dose milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose milk protein (pasteurized milk and milk protein powder)
Study: 32319204
Drug: High-dose milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose milk protein (condensed milk)
Study: 35302197
Drug: Sodium bicarbonated
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonated Ringer's solution
Study: 32488427
Drug: Trazodone ER
Normalized name: trazodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone ER formulation (300 mg)
Study: 32488427
Drug: Originator Trittico
Approvals — FDA: no, EMA: no, PMDA: no
Description: Originator Trittico XR (300 mg)
Study: 35921451
Drug: Prasinezumab 1500
Normalized name: Prasinezumab
DrugBank: Prasinezumab (DB14788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasinezumab 1500 mg
Study: 35921451
Drug: Prasinezumab 4500
Normalized name: Prasinezumab
DrugBank: Prasinezumab (DB14788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasinezumab 4500 mg
Study: 35921451
Drug: Infusion reactions
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion reactions
Study: 32794259
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg aldafermin
Study: 32794259
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg aldafermin
Study: 32794259
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg aldafermin
Study: 32794259
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg aldafermin
Study: 34521108
Drug: Id-KLH vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Id-KLH vaccine
Study: 32632489
Drug: WI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: WI plus L-TAP
Study: 35034023
Drug: Titration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration group
Study: 33825070
Drug: PA +
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PA + Charity (N=26; Fitbit, step goal, electronic weekly newsletter + charity donation if step goal achieved)
Study: 33825070
Drug: PA (N=25;
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA (N=25; Fitbit, step goal, electronic weekly newsletter)
Study: 32545062
Drug: Iron tablets
Normalized name: Iron 65 MG Oral Tablet [LEADER IRON TABLETS]
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron tablets
Study: 35316569
Drug: Thrombosis events
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thrombosis events (TE) during therapy for ALL
Study: 33394100
Drug: Antiparkinsonian medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparkinsonian medication
Study: 37384061
Drug: Oral metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronomic adjuvant chemotherapy (MAC) consisting of weekly methotrexate (15 mg/m2) and celecoxib (200 mg PO BD) for 18 months
Study: 33509019
Drug: Breviscapine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breviscapine (120 mg daily for 14 days)
Study: 34649982
Drug: High-dose CIMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CIMT
Study: 34649982
Drug: Moderate-dose CIMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose CIMT
Study: 34649982
Drug: Usual Customary
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Customary Treatment (UCT)
Study: 32597565
Drug: NBD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBD regimen (sequential nephron blockade with diuretics)
Study: 32597565
Drug: RASB regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: RASB regimen (sequential renin-angiotensin system blockade)
Study: 33551347
Drug: ACLA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACLA group (colloidal bismuth pectin 200 mg thrice a day, lansoprazole 30 mg twice a day, amoxicillin 1 g twice a day, antofloxacin 200 mg once a day)
Study: 33551347
Drug: LCLA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCLA group (levofloxacin 500 mg once a day)
Study: 34308678
Drug: Cold rub
Normalized name: Vaporizing Cold Rub
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold rub gel
Study: 36084714
Drug: Chemotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy after stent placement
Study: 32176092
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine Shenqi Compound
Study: 32176092
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment combined with Chinese medicine placebo
Study: 33588801
Drug: Prophylactic metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic metformin 500 mg twice daily for 72 hours
Study: 38918695
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) for 8 weeks
Study: 34532888
Drug: Itraconazole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (all doses)
Study: 36468403
Drug: Active BP
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active BP lowering treatment (combination perindopril±indapamide)
Study: 33476415
Drug: Oral sulfate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfate solution same-day dose (n=200)
Study: 33476415
Drug: Oral sulfate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfate solution split-dose (n=202)
Study: 38174567
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and placebo
Study: 36484364
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (3 times per week during irradiation, diode laser: 660 nm, 75 mW, 1.5 cm2, 50 mW/cm2, 60 seconds exposure, 3 J/cm2, 20-30 spots per session)
Study: 36484364
Drug: Sham low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham low-level laser therapy (identical delivery method to low-level laser therapy)
Study: 32784153
Drug: Loaded Dix-Hallpike
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loaded Dix-Hallpike (L-DH)
Study: 36317751
Drug: SHR4640 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640 (10 mg) under fed conditions
Study: 36317751
Drug: SHR4640 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640 (10 mg) under fasted conditions
Study: 36317751
Drug: SHR4640 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640 (10 mg)
Study: 32853584
Drug: Eltrombopag 50
Normalized name: eltrombopag 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 50 mg orally daily from 21 days preoperatively to postoperative day 7
Study: 32853584
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin 1 g/kg or 2 g/kg 7 days before surgery
Study: 32853584
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (per-protocol analysis)
Study: 35768027
Drug: Treatment received
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment received aligned with recommendations
Study: 35768027
Drug: Discordant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discordant treatment recommendations
Study: 35768027
Drug: Urologists' and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urologists' and radiation oncologists' treatment recommendations
Study: 32464351
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of 5-Hydroxytryptophan (5-HTP) daily
Study: 36125279
Drug: Lasmiditan 50
Normalized name: lasmiditan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasmiditan 50 mg
Study: 34229295
Drug: Epidemiological research,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidemiological research, case studies, single-arm treatment studies, randomized controlled treatment trials, and objective sleep study data
Study: 33749219
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed freehand by experienced clinicians
Study: 33017456
Drug: 90 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g/day low-carbohydrate diet (LCD)
Study: 32172599
Drug: Antiretroviral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral Therapy (ART) adherence strategies
Study: 32195538
Drug: Daily isocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily isocaloric meal with standardized amount of avocado (males: 175 g; females: 140 g) for 12 weeks
Study: 32195538
Drug: Daily isocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily isocaloric meal with standardized amount of avocado
Study: 35602971
Drug: BCAA (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (30 g, b.i.d. for 21 days)
Study: 35602971
Drug: Microcrystalline cellulose
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose (placebo, 30 g, b.i.d. for 21 days)
Study: 35602971
Drug: Rice protein
Normalized name: rice protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice protein (placebo, 30 g, b.i.d. for 21 days)
Study: 34391828
Drug: Statins treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins treatment
Study: 34391828
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy combined with statins
Study: 33857412
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for up to 18 doses
Study: 33857412
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for up to 18 doses in PD-L1-positive patients
Study: 36453188
Drug: Povidone-iodine rectal
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine rectal cleansing
Study: 36453188
Drug: No povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No povidone-iodine rectal cleansing (Control)
Study: 35287025
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) administered three times (median, range 1–5 times), with an interval of 9.5 months (mean [SD]) under B cell monitoring.
Study: 35287025
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) monotherapy, 28 (90%) of 31 patients treated with RTX.
Study: 35287025
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) administration under B cell monitoring.
Study: 32156544
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h continuous infusion)
Study: 33819508
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) and Sublingual immunotherapy (SLIT)
Study: 35570699
Drug: Oral SDX
Normalized name: METAP2 inhibitor SDX-7320
DrugBank: Evexomostat (DB19140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SDX (120 mg)
Study: 35570699
Drug: Oral SDX
Normalized name: METAP2 inhibitor SDX-7320
DrugBank: Evexomostat (DB19140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SDX (240 mg)
Study: 35570699
Drug: IN SDX
Normalized name: METAP2 inhibitor SDX-7320
DrugBank: Evexomostat (DB19140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN SDX (80 mg)
Study: 35570699
Drug: IV SDX
Normalized name: METAP2 inhibitor SDX-7320
DrugBank: Evexomostat (DB19140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV SDX (30 mg)
Study: 35570699
Drug: d-MPH (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-MPH (80 mg)
Study: 35570699
Drug: d-MPH (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-MPH (40 mg)
Study: 35570699
Drug: d-MPH (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-MPH (15 mg)
Study: 33025052
Drug: Episealer implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episealer implant
Study: 36316692
Drug: Low pre-RRT
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low pre-RRT penKid levels (penKid ≤ 89 pmol/l)
Study: 36316692
Drug: Low pre-RRT
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low pre-RRT penKid levels (penKid ≤ 89 pmol/l) at day 3 of RRT
Study: 36409018
Drug: Duloxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30 mg, doubled if no response at 2 weeks)
Study: 32996010
Drug: D-Mg2+ at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Mg2+ at 0.75 mmol/L
Study: 33066944
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin therapy in combination with dynamic electric neurostimulation and basic therapy
Study: 33066944
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin therapy and basic therapy
Study: 33066944
Drug: Dynamic electric
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic electric neurostimulation and basic therapy
Study: 37942277
Drug: tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 5 mg twice daily
Study: 36329128
Drug: Combined pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pressure garment and topical silicone gel therapy
Study: 36461619
Drug: Facemask pre-oxygenation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facemask pre-oxygenation (100% oxygen, 6 L/min)